Key Events This Week
11 May: Stock opens at Rs.1,279.70, down 1.05% amid broad market weakness
12 May: Q4 FY26 results reveal sharp margin compression and 86% profit crash
13 May: Significant gap down opening at Rs.1,220.20 reflecting market concerns
14 May: Intraday high surge of 3.15% to Rs.1,302.85, technical and quality grade downgrades announced
15 May: Intraday high of Rs.1,338.50 with 3.05% gain, technical momentum shifts bullish
11 May 2026: Market Weakness Sets the Tone
Dr Reddys Laboratories Ltd opened the week at Rs.1,279.70, down 1.05% from the previous Friday’s close of Rs.1,293.25. The decline occurred amid a broader Sensex drop of 1.40%, closing at 35,679.54. Trading volume was moderate at 47,674 shares. The stock’s performance mirrored the cautious market sentiment as investors digested sector and macroeconomic factors.
12 May 2026: Earnings Shock and Technical Momentum Shift
The company reported a sharp margin compression in its Q4 FY26 results, triggering an 86% profit crash. Net sales fell to ₹7,546.40 crore with operating profit margins contracting to 5.07%. The operating profit before depreciation and interest dropped to ₹382.50 crore, while interest expenses surged to ₹105.70 crore, pressuring coverage ratios. Earnings per share declined to ₹2.65, the lowest in recent quarters.
Following the results, the stock closed at Rs.1,270.10, down 0.75%. Technical momentum shifted from bullish to mildly bullish, reflecting mixed signals from MACD, RSI, and moving averages. Despite the profit shock, the stock remained above its 52-week low, showing some resilience.
13 May 2026: Gap Down Opening Amid Market Concerns
Dr Reddys Laboratories Ltd opened sharply lower at Rs.1,220.20, a 3.93% gap down from the previous close, reflecting investor apprehension following the earnings release and broader market weakness. The stock’s intraday high of Rs.1,303.55 indicated some recovery, but it closed down 1.28%, underperforming the Sensex’s marginal 0.06% decline. The five-day losing streak culminated in a cumulative 3.6% loss, highlighting short-term selling pressure.
14 May 2026: Intraday High and Quality Grade Downgrade
The stock rebounded strongly, surging 3.15% intraday to Rs.1,302.85, outperforming both its sector and the Sensex. This recovery was supported by the stock trading above all key moving averages, signalling a strengthening trend. However, MarketsMOJO downgraded the company’s quality grade from excellent to good, citing moderate returns on equity and capital employed, and a fair valuation grade replacing an earlier attractive rating.
The valuation shift reflected a P/E ratio of 25.33 and a price-to-book value of 2.80, positioning Dr Reddys as fairly valued relative to peers. Despite the downgrade, the stock’s fundamentals remain solid, supported by low leverage and consistent growth metrics.
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
15 May 2026: Bullish Technical Momentum and Strong Finish
Dr Reddys Laboratories Ltd demonstrated robust intraday strength, surging 3.05% to an intraday high of Rs.1,338.50, just 3.06% below its 52-week high of Rs.1,377.95. The stock outperformed its sector by 2.23% and the Sensex, which declined 0.16%. Technical indicators shifted from mildly bullish to outright bullish, supported by positive MACD readings on weekly and monthly charts, bullish Bollinger Bands, and strong moving averages alignment.
The stock closed the week at Rs.1,336.95, marking a 3.38% gain from the previous Friday’s close. Despite the recent downgrade to a Hold rating and a Mojo Score of 58.0, the stock’s technical profile suggests potential for further upside, tempered by mixed volume and Dow Theory signals.
Dr Reddys Laboratories Ltd or something better? Our SwitchER feature analyzes this large-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Daily Price Comparison: Dr Reddys Laboratories Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-05-11 | Rs.1,279.70 | -1.05% | 35,679.54 | -1.40% |
| 2026-05-12 | Rs.1,270.10 | -0.75% | 34,899.09 | -2.19% |
| 2026-05-13 | Rs.1,265.10 | -0.39% | 35,010.26 | +0.32% |
| 2026-05-14 | Rs.1,302.80 | +2.98% | 35,364.44 | +1.01% |
| 2026-05-15 | Rs.1,336.95 | +2.62% | 35,236.50 | -0.36% |
Key Takeaways
Positive Signals: The stock’s 3.38% weekly gain amid a 2.63% Sensex decline highlights relative strength. Intraday highs on 14 and 15 May above Rs.1,300 indicate renewed buying interest. Technical momentum shifted bullish by week’s end, supported by MACD, moving averages, and Bollinger Bands. The company’s low leverage and consistent sales growth underpin its fundamental stability.
Cautionary Notes: The sharp Q4 profit decline and margin compression signal operational challenges. Downgrades in quality and valuation grades reflect moderated fundamentals and price attractiveness. Mixed volume indicators and Dow Theory signals suggest potential short-term volatility. The Hold rating and Mojo Score of 58.0 advise measured optimism rather than aggressive accumulation.
Conclusion
Dr Reddys Laboratories Ltd navigated a challenging week marked by disappointing quarterly results and technical shifts, yet closed with a notable 3.38% gain outperforming the Sensex by over 6 percentage points. The stock’s rebound and bullish technical momentum suggest resilience and potential for further gains, although fundamental headwinds and rating downgrades counsel caution. Investors should monitor upcoming financial updates and technical signals closely to gauge sustainability of the current momentum within the Pharmaceuticals & Biotechnology sector’s evolving landscape.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
